Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy
This article was originally published in PharmAsia News
Executive Summary
Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.
You may also be interested in...
Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
Need a specific report? 1000+ reports available
Buy Reports